Review Article

Effectiveness and Safety of Controlled Venous Pressure in Liver Surgery: A Systematic Review and Network Meta-Analysis

Xue Liang Zhang,^{1,2} Wen Ji Wang,¹ Wen Jin Wang,³ and Nong Cao^{2,4}

¹Department of Orthopaedic, The First Hospital of Lanzhou University, Lanzhou 730000, China ²Lanzhou University, Lanzhou 730000, China

³Department of Emergency, The First Hospital of Lanzhou University, Lanzhou 730000, China

⁴Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China

Correspondence should be addressed to Nong Cao; cao_nong126@126.com

Received 18 January 2015; Accepted 16 April 2015

Academic Editor: Hynek Pikhart

Copyright © 2015 Xue Liang Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate the effectiveness and safety of controlled venous pressure in liver surgery and further to compare the clinical outcomes of low central venous pressure by infrahepatic inferior vena cava clamping (IVCC) and intraoperative anesthetic control (IAC). *Methods.* Online databases including PubMed, Embase, Cochrane Library, Clinical trials.gov, and China biology medicine database were comprehensively searched. After identifying relevant studies out of the search results, quality assessment was performed according to the methods recommended by the Cochrane collaboration. And meta-analysis was performed by both direct comparison and indirect comparison. *Results.* Thirteen studies containing 1252 patients were included. Compared with control, controlled venous pressure significantly decreased central venous pressure, total blood loss, blood loss during transection, transfusion rate, and total incidence of complications. Further analysis of IVCC and IAC showed that there was no significant difference in aspects of main clinical outcomes. *Conclusions.* Controlled venous pressure significantly decreased central venous pressure and achieved improvement of bleeding control in liver surgery. It reduced total incidence of complications and chest infection, while it caused concerns about heart disorder. Although IVCC was not worse than IAC in therapeutic effect, a superiority between them still needs to be explored.

1. Introduction

As known, acute and long-term severe liver disease mainly including alcoholic and viral hepatitis can lead to an endstage function failure. Besides, many uncontrolled chronic hepatitis patients will finally progress to be cirrhosis, which has a high risk to be malignant tumors [1]. For the treatment of function failure and tumors, liver transplantation and hepatectomy are regarded as the most curative ones [2]. It was reported that annually around 5700 liver transplantations were performed in Europe and 6000 cases in USA [3].

Nearly 14% of the whole blood is stored in liver, so liver surgery is always associated with high volumes of blood loss. In order to control bleeding from inflow system of liver blood supply, surgeons need to perform Pringle maneuver or selective vascular occlusion [4], and it is demonstrated to be effective. Meanwhile, some studies reported that a low central venous pressure (LCVP) also contributed an improvement in blood loss [5, 6], and this may control bleeding from outflow system of liver blood supply. Currently a LCVP was mostly achieved by intraoperative anesthetic control (IAC) and infrahepatic inferior vena cava clamping (IVCC). Compared with IAC, IVCC was considered to be easier to realize, and might to some extent ease concerns about abnormal homodynamic [7, 8].

Many clinical studies were designed to investigate the effectiveness and safety of controlled venous pressure in liver hepatectomy, liver resection, and transplantation [9]. However, the results were not completely consistent, and there were still no certain answers. Therefore, we performed a meta-analysis to define the therapeutic effect and safety of controlled venous pressure in liver surgery, and a network meta-analysis to further explore the difference between IAC and IVCC in clinical outcomes.

2. Materials and Methods

2.1. Search Strategy. Online databases including PubMed (1966.01–2014.12), Cochrane Library (2014 Issue 12), Embase (1974.01–2014.12), and China biology medicine database (up to 2014.12) were systematically searched. Search terms were ("infrahepatic inferior vena cava clamping" OR "IVC clamping" OR "IVCC" OR "low central vena cava pressure" OR "LCVP" OR "low central vena cava pressure" OR "LCVP" OR "low central vena cava pressure" OR "LCVP" OR "low central vena cava pressure" OR "liver surgery" OR "hepatic operation" OR "hepatectomy" OR "liver transplantation"). Medical subject headings, related articles function, and the references of reviews were also screened to widen the search results.

2.2. Literature Inclusion Criteria. The literature search results were firstly scanned by titles and abstracts, and eligibility for inclusion was further evaluated by reading full-texts by two reviewers independently (Wang Wen Ji, Zhang Xue Liang). Clinical studies investigating the method of controlled venous pressure in liver surgery were eligible. Patients with severe hepatic disease and who were willing to undergo a hepatectomy, liver resection, and transplantation were participants. All the characteristics of participants and treatment were comparable between treatment group and control group, except for the additional intervention of controlled venous pressure. The main outcome measures to evaluate therapeutic effect were total blood loss and blood loss during transection. Secondary outcome measures were transfusion rate, liver transection time, central venous pressure, and incidence of complications.

2.3. Data Extraction and Quality Assessment. Two reviewers (Zhang Xue Liang, Wang Wen Ji) extracted the information of the included studies, which mainly included author, publication year, group, cases, age, surgical procedures, and the data of outcome measures. Methodological quality of randomized controlled studies was assessed by using and modifying the methods recommended in the Cochrane handbook [10], which were based on six items: randomization, allocation concealment, blinding, comparative baseline, follow-up, and selective reporting. For high-quality comparative studies, Newcastle-Ottawa scale (NOS) was adopted to assess methodological quality, which was mainly based on patients selection, baseline comparability, and outcome measure [11]. Any disagreement about eligible and quality assessment were resolved through discussion or by a third reviewer (Cao Nong).

2.4. Statistical Analysis. Meta-analysis was conducted by using RevMan software (version 5.3, the Cochrane collaboration, Copenhagen, Denmark). The heterogeneity between studies was judged by Chi-square and I^2 statistical test. Random-effect model or fixed-effect model was chosen according to the heterogeneity test results. Pooled risk ratios (RR), mean difference (MD), and standard mean difference (SMD), with their 95% confidence intervals (95% CI), were presented for effect size. Network meta-analysis was conducted by using ITC soft (version 1.0, Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada) [12]. The indirect comparison was handled and then a result in terms of statistical superiority/inferiority or no difference between the groups was assigned, and effect size with respective 95% CI was also presented.

This meta-analysis was conducted and reported mainly according to The Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement.

3. Results

3.1. Flow Diagram of Trial Selection. A total of thirteen trials [13–25] containing 1252 patients were included. There are 601 cases in the treatment group and 651 cases in the control group. Six of them [13, 14, 16, 18, 20, 23] compared IVCC with control, five of them [15, 17, 19, 24, 25] compared IAC with control, and two of them [21, 22] compared IVCC with IAC. Figure 1 shows the flow chart from literature search result to final trial inclusion. The basic information of the included studies was extracted and described in Table 1. Nine of included studies were RCTs, and four of them were high-quality studies with more than 5 stars. The result of methodological quality assessment of included randomized controlled trials was shown in Table 2.

3.2. Meta-Analysis of Controlled Venous Pressure with Control. Compared with control, controlled venous pressure in liver surgery achieved a significant decrease in outcomes of central venous pressure [$I^2 = 95\%$, MD = -2.67, 95% CI (-4.26, -1.09), P = 0.0009, Figure 3], total blood loss [$I^2 = 95\%$, SMD = -0.81, 95% CI (-1.09, -0.54), P < 0.0001, Figure 4], blood loss during transection [$I^2 = 84\%$, SMD = -0.99, 95% CI (-1.48, -0.50), P < 0.0001, Figure 5], and transfusion rate [$I^2 = 2\%$, RR = 0.48, 95% CI (0.36, 0.64), P < 0.0001, Figure 6].

Further analysis of liver transection time indicated that there was no significant difference between the groups $[I^2 =$ 9%, MD = -0.46, 95% CI (-1.68, 0.75), P = 0.45, Figure 7]. Controlled venous pressure also decreased total incidence of complications $[I^2 = 0\%, RR = 0.75, 95\%$ CI (0.63, 0.91), P = 0.003, Table 3], and main diagnosis of complications was presented in Table 3, in which only chest infection finally reached a significant difference $[I^2 = 0\%, MD = 0.56, 95\%$ CI (0.35, 0.90), P = 0.02].

3.3. Subgroup Analysis Comparing IVCC with Control. Compared with control, IVCC significantly reduced central venous pressure $[I^2 = 94\%, MD = -2.40, 95\% \text{ CI} (-4.13, -0.66),$ P = 0.007, Figure 3], total blood loss $[I^2 = 68\%, SMD =$ -0.64, 95% CI (-0.98, -0.31), P < 0.0001, Figure 4], blood loss during transection $[I^2 = 91\%, SMD = -1.01\,95\% \text{ CI} (-1.80,$ -0.23), P = 0.01, Figure 5], transfusion rate $[I^2 = 38\%, RR =$ 0.46, 95% CI (0.32, 0.65), P < 0.0001, Figure 6], and total incidence of complications $[I^2 = 0\%, RR = 0.75, 95\% \text{ CI} (0.63,$ 0.91), P = 0.003, Table 3], whereas no significant difference



FIGURE 1: Flow chart of trial selection.



FIGURE 2: Network diagram of clinical trials according to the methods used to control venous pressure. A represented IVCC, B represented IAC, and C represented control.

Study or subgroup	LC	CVP gr	oup	Cont	rol gr	oup		Mean difference	Mean difference	
Study of subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	IV, random, 95% CI	
1.2.1 IVCC versus con	trol									
Otsubo et al. 2004	6.9	2.4	47	10.1	2.8	56	16.5%	-3.20 [-4.20, -2.20]		
Chen et al. 2006	5.3	1.5	60	5.2	1.8	58	17.3%	0.10 [-0.50, 0.70]	- - -	
Kato et al. 2008	4	3.25	43	6	3.25	42	15.6%	-2.00 [-3.38, -0.62]		
Uchiyama et al. 2009	2.4	1.8	20	5.6	2.2	58	16.6%	-3.20 [-4.17, -2.23]		
Liu et al. 2010	3.99	1.87	67	7.74	3.68	83	16.7%	-3.75 [-4.66, -2.84]		
Subtotal (95% CI)			237			297	82.7%	-2.40 [-4.13, -0.66]	\bullet	
Heterogeneity: $\tau^2 = 3$.	68; $\chi^2 =$: 71.85	, df = 4	(P < 0.)	00001); $I^2 =$	94%			
Test for overall effect:	Z = 2.70	P = 0	0.007)							
1.2.2 IAC versus control	ol									
Feng et al. 2010	6	1	43	10	1.75	43	17.3%	-4.00 [-4.60, -3.40]	-	
Subtotal (95% CI) Heterogeneity: not app	olicable		43			43	17.3%	-4.00 [-4.60, -3.40]	•	
Test for overall effect:	Z = 13.0)1 (P <	0.0000	01)						
Total (95% CI)			280			340	100.0%	-2.67 [-4.26, -1.09]	•	
Heterogeneity: $\tau^2 = 3$.	68; $\chi^2 =$	107.7	df = 5	(P < 0.0)	00001)	; $I^2 =$	95%	Т		—
Test for overall effect:	Z = 3.31	(P = 0	0.0009))				-10	0 -5 0 5	10
Test for subgroup diffe	rences: ;	$\chi^2 = 2.$	92, df =	= 1 (<i>P</i> =	0.09)	$I^2 = \epsilon$	55.7%		LCVP group Control group	

FIGURE 3: Meta-analysis of central venous pressure between LCVP and control.

			IABLI	e li Chiala	rictistic	s of filtrance stu	mes.		
Study	Country	Case $(T/C, n)$	Age (T/C, y)	Sex (N T	4/F) C	Intervention	Baseline CVP (T/C)	Surgery	Diagnosis
Otsubo et al. 2004 [13]	Japan	47/56	59.3 ± 14.4/55.4 ± 16.1	30/17	41/15	IVCC/control	10.6 ± 2.6/10.1 ± 2.8	Hepatectomy	Hepatocarcinoma (28/31), metastatic tumor (10/14), cholangiocellular carcinoma (5/4), others (4/7)
Chen et al. 2006 [14]	China	60/58	39.7 ± 3.6/41.5 ± 4.1	53/7	51/7	IVCC/control	7.6 ± 3.0/7.7 ± 2.4	Hepatectomy	HBV related cirrhosis (51/54), HCV related cirrhosis (6/4), others (1/2)
Wang et al. 2006 [15]	China	25/25	$45.3 \pm 14.6/46.0 \pm 12.1$	19/6	21/4	IAC/control	I	Hepatectomy	Liver cirrhosis (14/15), others (11/10)
Kato et al. 2008 [16]	Japan	43/42	65 (28–82)/67 (38–79)*			IVCC/control	7 (3–14)/7 (2–16)*	Liver resection	Hepatocarcinoma (35/34), metastatic tumor (6/7), cholangiocellular (1/0)
Liu et al. 2008 [17]	China	23/23	$45.4 \pm 13.0/42.9 \pm 12.6$	14/9	16/7	IAC/control	2.7-5.4	Liver resection	Hepatocarcinoma (23/23)
Uchiyama et al. 2009 [18]	Japan	20/58	$61.6 \pm 12.9/64.8 \pm 16.8$	15/5	44/14	IVCC/control	I	Hepatectomy	Hepatocarcinoma (9/31), metastatic tumor (6/20), others (5/7)
Feng et al. 2010 [19]	China	43/43	$48 \pm 10/47 \pm 12$	6/37	8/35	IAC/control	10 (6–12)/10 (6–11)*	Transplantation	Hepatocirrhosis (15/16), severe hepatitis (7/8), carcinoma (19/17), others (2/2)
Liu et al. 2010 [20]	China	67/83	51 (33–69)/55 (14–76)*	48/35	55/12	IVCC/control	7.8 ± 3.5/8.3 ± 3.6	Liver lobectomy	Primary liver carcinoma (67/83)
Rahbari et al. 2011 [21]	Germany	65/63	57.2 ± 10.9/59.2 ± 12.1	37/28	42/21	IVCC/IAC	9.2 ± 3.6/7.6 ± 3.6	Liver resection	Hepatocarcinoma (19/20), metastatic tumor (35/37), others (11/6)
Zhu et al. 2012 [22]	China	96/96				IVCC/IAC	$10.5 \pm 1.3/10.8 \pm 1.2$	Liver resection	Liver tumors (96/96)
Yang et al. 2013 [23]	China	60/53	$48.7 \pm 10.8/49.5 \pm 12.1$	43/17	38/15	IVCC/control	7.6 ± 3.2/	Hepatectomy	Hepatocarcinoma (31/26), metastatic tumor (7/7), others (22/20)
Ryu et al. 2010 [24]	South Korea	19/19	$29 \pm 11/26 \pm 9$	15/3	18/1	IAC/control	8.5/7.5	Liver lobectomy	Donors (19/19)
Wang et al. 2013 [25]	China	33/32	$37.1 \pm 10.1/35.9 \pm 10.3$	26/7	26/6	IAC/control	I	Liver lobectomy	Hepatocarcinoma (11/18), hepatocirrhosis (16/12), hepatitis B (4/1), others (2/1)
IVCC: infrahepatic inferior v. *Data were presented as med.	ena cava clamping; ian (range).	; IAC: low cen	ıtral vein pressure by intra	operative a	unesthetic	c control; T: treatm	ent group; C: control gro	up.	

TABLE 1: Characteristics of included studies

4

Study	Randomization	Blinding	Allocation concealment	Comparative baseline	>80% follow-up	Free of selective reporting
Chen et al. 2006 [14]	Mentioned	Unclear	Unclear	Yes	Yes	Yes
Wang et al. 2006 [15]	Yes	Yes	Yes	Yes	Yes	Yes
Kato et al. 2008 [16]	Yes	Unclear	Unclear	Yes	Yes	Yes
Liu et al. 2008 [17]	Mentioned	Yes	Unclear	Yes	Yes	Yes
Feng et al. 2010 [19]	Yes	Yes	Yes	Yes	Yes	Yes
Rahbari et al. 2011 [21]	Yes	Yes	Yes	Yes	Yes	Yes
Zhu et al. 2012 [22]	Yes	Yes	Yes	Yes	Yes	Yes
Ryu et al. 2010 [24]	Yes	Yes	Yes	Yes	Yes	Yes
Wang et al. 2013 [25]	Yes	Yes	Yes	Yes	Yes	Yes

Yes: the method was properly adopted and used; mentioned: the method was reported without detailed description; unclear: no relevant information was found.



FIGURE 4: Meta-analysis of total blood loss between LCVP and control.

was found in liver transection time [$I^2 = 0\%$, MD = -0.24, 95% CI (-1.52, 1.04), P = 0.71, Figure 7].

3.4. Subgroup Analysis Comparing IAC with Control. Compared with control, IAC significantly decreased central venous pressure [MD = -4.00 95% CI (-4.60, -3.40), P <0.0001, Figure 3], total blood loss [$I^2 = 70\%$, SMD = -1.05, 95% CI (-1.52, -0.57), P < 0.0001, Figure 4], blood loss during transection [$I^2 = 39\%$, SMD = -0.97, 95% CI (-1.44, -0.50), P < 0.0001, Figure 5], transfusion rate [$I^2 = 0\%$, RR = 0.56, 95% CI (0.34, 0.91), P = 0.02, Figure 6], and total incidence of complications [$I^2 = 0\%$, RR = 0.68, 95% CI (0.55, 0.86), P = 0.0009, Table 3]. There were also no significant differences in aspects of liver transection time $[I^2 = 25\%, MD = -2.36, 95\% \text{ CI} (-6.10, 1.37), P = 0.22, Figure 7].$

3.5. Network Meta-Analysis of IVCC with IAC. Due to insufficient numbers and cases of direct comparison, we also performed a network meta-analysis. Figure 2 shows the network of clinical studies according to the methods used to control central venous pressure. Two studies compared IVCC with IAC; meta-analysis results indicated that IVCC significantly decreased total blood loss, blood loss during transection, total operation time, and liver transection time. However, the network analysis results showed that there were no significant difference in aspects of central venous pressure,

Study or subgroup	LC	CVP gro	up	Cont	rol grou	ıp		Std. mean difference		Std. mea	n difference	
Study of subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI		IV, rando	om, 95% CI	
1.5.1 IVCC versus cont	rol											
Chen et al. 2006	350	110	60	680	280	58	20.5%	-1.55 [-1.96, -1.14]				
Kato et al. 2008	233	208.75	43	285	347.25	5 42	20.3%	-0.18 [-0.61, 0.25]		-	╞┿	
Liu et al. 2010	263	146	67	657	384	83	21.3%	-1.30 [-1.65, -0.94]				
Rahbari et al. 2011	150	103.75	65	400	125	63		Not estimable				
Subtotal (95% CI)			170			183	62.1%	-1.01 [-1.80, -0.23]		\bullet		
Heterogeneity: $\tau^2 = 0.4$	44; $\chi^2 =$	23.52,	df = 2	P < 0	.00001)	; $I^2 =$	91%					
Test for overall effect: 2	Z = 2.53	B(P=0)	0.01)									
1.5.2 IAC versus contro	ol											
Wang et al. 2006	672.4	429.9	25	1,662.6	1,932.	1 25	18.1%	-0.70 [-1.27, -0.12]			-	
Feng et al. 2010	1,058	685	43	1,991	874	43	19.8%	-1.18 [-1.64, -0.72]				
Subtotal (95% CI)			68			68	37.9%	-0.97 [-1.44, -0.50]				
Heterogeneity: $\tau^2 = 0.0$ Test for overall effect: 2	$25; \chi^2 = 2$	= 1.65, d 5 (P < 0	f = 1 (0.0001)	(P = 0.2)	0); I ² =	= 39%						
Total (95% CI)			238			251	100.0%	-0.99 [-1.48, -0.50]		•		
Heterogeneity: $\tau^2 = 0.2$ Test for overall effect: 2	$26; \chi^2 = Z = 3.96$	= 25.27, 5 (P < 0	df = 4	(P < 0.	0001);	$I^2 = 8$	4%		-4	-2	0 2	4
Test for subgroup differ	rences:	$\chi^2 = 0.0$	01, df :	= 1 (P =	= 0.92),	$I^2 = 0$	0%			LCVP group	Control group)

FIGURE 5: Meta-analysis of liver transected blood loss between LCVP and control.

Study on sub-succes	LCVP §	group	Control	group		Risk ratio	Risk ratio
Study of subgroup	Events	Total	Events	Total	Weight	M-H, fixed, 95% CI	M-H, fixed, 95% CI
1.8.1 IVCC versus con	ntrol						
Otsubo et al. 2004	15	47	25	56	22.1%	0.71 [0.43, 1.19]	
Yang et al. 2013	5	60	12	53	12.3%	0.37 [0.14, 0.98]	_
Chen et al. 2006	8	60	27	58	26.6%	0.29 [0.14, 0.58]	_ _
Uchiyama et al. 2009	4	20	26	58	12.9%	0.45 [0.18, 1.12]	
Subtotal (95% CI)		187		225	73.9%	0.46 [0.32, 0.65]	\bullet
Total events	32		90				•
Heterogeneity: $\chi^2 = 4$	4.87, df = 3	(P = 0.18)	; $I^2 = 389$	6			
Test for overall effect:	Z = 4.39 (P < 0.000	1)				
1.8.2 IAC versus cont	rol						
Wang et al. 2006	8	25	14	25	13.5%	0.57 [0.29, 1.12]	
Liu et al. 2008	7	23	13	23	12.6%	0.54 [0.26, 1.10]	
Subtotal (95% CI)		48		48	26.1%	0.56 [0.34, 0.91]	\bullet
Total events	15		27				-
Heterogeneity: $\chi^2 = 0$	0.01, df = 1	(P = 0.91); $I^2 = 0\%$)			
Test for overall effect:	Z = 2.36 (P = 0.02)					
Total (95% CI)		235		273	100.0%	0.48 [0.36, 0.64]	•
Total events	47		117				•
Heterogeneity: $\chi^2 = 5$ Test for overall effect:	5.08, df = 5 Z = 4.99 ((P = 0.41) P < 0.0000); $I^2 = 2\%$ (01)			0.01	
Test for subgroup diff	Therefore the formation χ^2	= 0.41, df	f = 1 (P =	0.52), I ²	= 0%	0.01	LCVP group Control group

FIGURE 6: Meta-analysis of transfusion rate between LCVP and control.

total blood loss, total operation time, liver transection time, transfusion rate, and total complications, as shown in Table 4.

3.6. Publication Bias. Inverted funnel plots were adopted to evaluate publication bias. The results of transfusion rate, liver transection time, and total complications did not reveal

Study or subgroup	LC	CVP gro	oup	Contr	rol gro	oup		Mean difference		Mean di	ifference	
Study of subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, fixed, 95% CI		IV, fixed	, 95% CI	
1.7.1 IVCC versus con	trol											
Chen et al. 2006	13.6	3.3	60	13.9	3.8	58	88.7%	-0.30 [-1.59, 0.99]				
Kato et al. 2008	55	23.25	43	49	37.5	42	0.8%	6.00 [-7.30, 19.30]				
Subtotal (95% CI)			103			100	89.5%	-0.24 [-1.52, 1.04]			•	
Heterogeneity: $\chi^2 = 0$.	.85, df =	1 (P =	0.36);	$I^2 = 0\%$								
Test for overall effect:	Z = 0.37	7 (P = 0)	0.71)									
1.7.2 IAC versus control	ol											
Ryu et al. 2010	71	20	18	67	15	19	1.1%	4.00 [-7.44, 15.44]				-
Liu et al. 2008	18.23	6.54	23	21.35	7.12	23	9.4%	-3.12 [-7.07, 0.83]			+	
Subtotal (95% CI)			41			42	10.5%	-2.36 [-6.10, 1.37]				
Heterogeneity: $\chi^2 = 1$.	.33, df =	1 (P =	0.25);	$I^2 = 259$	%					-		
Test for overall effect:	Z = 1.24	P = 0	0.22)									
Total (95% CI)			144			142	100.0%	-0.46 [-1.68, 0.75]				
Heterogeneity: $\chi^2 = 3$.	.29, df =	= 3 (P =	= 0.35);	$I^2 = 99$	%						<u> </u>	
Test for overall effect:	Z = 0.75	5(P = 0)).45)						-20	-10	0 10	20
	_ 0070	2 1	11 10	1 (D	0.00)	7 2	0.70/			LCVP group	Control group	,
lest for subgroup diffe	erences:	$\chi = 1.$	11, df =	= 1 (P =	0.29)	, 1 =	9./%			2011 Sloup	Source Broad	Ĩ.

FIGURE 7: Meta-analysis of liver transected time between LCVP and control.

Study	Case	(n/N)	Heter	ogeneity	Effect size	
Study	LCVP	Control	I^2	Р	RR(95% CI)	P
[14, 18–20, 23, 25]	20/283	37/327	0%	0.96	0.56 (0.35, 0.90)	0.02
[14, 18–20, 23, 25]	41/283	57/327	43%	0.12	0.72 (0.51, 1.02)	0.06
[14, 23]	5/120	7/111	0%	0.75	0.64 (0.21, 1.93)	0.43
[14, 18, 23]	12/140	22/169	0%	0.81	0.56 (0.29, 1.08)	0.08
[18, 20]	1/87	2/141	0%	0.40	1.36 (0.19, 9.67)	0.76
[18, 20]	2/80	2/111	0%	0.75	1.41 (0.22, 9.23)	0.72
[18, 20]	0/80	3/111	0%	0.45	0.35 (0.05, 2.67)	0.31
[18, 20]	3/80	5/111	0%	0.49	0.90 (0.21, 3.85)	0.88
[18, 20]	3/103	4/101	0%	0.33	0.77 (0.20, 3.02)	0.71
[14, 18, 20, 23]	52/207	69/252	0%	0.50	0.83 (0.62, 1.11)	0.2
[15, 19, 25]	47/101	68/100	0%	0.70	0.68 (0.55, 0.86)	0.009
[14, 15, 18-20, 23, 25]	99/308	137/352	0%	0.71	0.75 (0.63, 0.91)	0.003
	Study [14, 18–20, 23, 25] [14, 18–20, 23, 25] [14, 23] [14, 18, 23] [18, 20] [18, 20] [18, 20] [18, 20] [18, 20] [14, 18, 20, 23] [15, 19, 25] [14, 15, 18–20, 23, 25]	Study Case LCVP [14, 18-20, 23, 25] 20/283 [14, 18-20, 23, 25] 41/283 [14, 18, 20] 5/120 [14, 18, 23] 12/140 [18, 20] 1/87 [18, 20] 2/80 [18, 20] 3/80 [18, 20] 3/103 [14, 18, 20, 23] 52/207 [15, 19, 25] 47/101	Case (n/N) LCVPStudyCase (n/N) LCVPControl[14, 18-20, 23, 25]20/28337/327[14, 18-20, 23, 25]41/28357/327[14, 23]5/1207/111[14, 18, 23]12/14022/169[18, 20]1/872/141[18, 20]2/802/111[18, 20]3/805/111[18, 20]3/1034/101[18, 20]3/1034/101[14, 18, 20, 23]52/20769/252[15, 19, 25]47/10168/100	Case (n/N) Heter LCVPLCVPControl I^2 [14, 18-20, 23, 25]20/28337/3270%[14, 18-20, 23, 25]41/28357/32743%[14, 23]5/1207/1110%[14, 18, 23]12/14022/1690%[18, 20]1/872/1410%[18, 20]2/802/1110%[18, 20]3/805/1110%[18, 20]3/1034/1010%[18, 20]3/1034/1010%[14, 18, 20, 23]52/20769/2520%[14, 18, 20, 23]52/20769/2520%[14, 15, 18-20, 23, 25]99/308137/3520%	Case (n/N) Heterogeneity $LCVP$ ControlI ² P[14, 18-20, 23, 25]20/283 $37/327$ 0%0.96[14, 18-20, 23, 25]41/283 $57/327$ 43%0.12[14, 23]5/1207/1110%0.75[14, 18, 23]12/14022/1690%0.81[18, 20]1/872/1410%0.40[18, 20]2/802/1110%0.45[18, 20]3/803/1110%0.45[18, 20]3/805/1110%0.49[18, 20]3/1034/1010%0.33[14, 18, 20, 23]52/20769/2520%0.50[15, 19, 25]47/10168/1000%0.70	StudyCase (n/N) LCVPHeterogeneity ControlEffect size RR(95% CI)[14, 18–20, 23, 25]20/28337/3270%0.960.56 (0.35, 0.90)[14, 18–20, 23, 25]41/28357/32743%0.120.72 (0.51, 1.02)[14, 23]5/1207/1110%0.750.64 (0.21, 1.93)[14, 18, 23]12/14022/1690%0.810.56 (0.29, 1.08)[18, 20]1/872/1410%0.401.36 (0.19, 9.67)[18, 20]2/802/1110%0.751.41 (0.22, 9.23)[18, 20]3/805/1110%0.450.35 (0.05, 2.67)[18, 20]3/805/1110%0.490.90 (0.21, 3.85)[18, 20]3/1034/1010%0.330.77 (0.20, 3.02)[14, 18, 20, 23]52/20769/2520%0.500.83 (0.62, 1.11)[14, 15, 18-20, 23, 25]99/308137/3520%0.710.75 (0.63, 0.91)

TABLE 3: Subgroup analysis of complications between LCVP and control group.

TABLE 4: Network analysis results between IVCC and IAC.

Outcomes	Direct comparison	1	Indirect compari	son
Outcomes	MD (95% CI)	Р	MD (95% CI)	GRADE
Central venous pressure	0.76 (-1.17, 2.70)	0.05	1.6 (-0.24, 3.44)	High
Total blood loss	-346.0 (-423.89, -268.12)	< 0.0001	180.81 (-72.4, 433.66)	Low
Blood loss during transection	-249.22 (-288.84, -209.61)	< 0.0001	677.69 (325.73, 1029.65)	Low
Operation time	-10.0 (-18.73, -1.28)	0.02	5.02 (-11.26, 21.3)	Moderate
Liver transected time	-2.17 (-3.23, -1.11)	< 0.0001	2.12 (-1.62, 5.86)	Low
	RR (95% CI)	Р	RR (95% CI)	Grade
Transfusion rate	0.83 (0.52, 1.32)	0.44	0.82 (0.45, 1.51)	High
Total complications	0.97 (0.77, 1.23)	0.80	1.22 (0.85, 1.76)	High

GRADE: Grading of Recommendations, Assessment, Development, and Evaluation.



FIGURE 8: Funnel plot. (a) Transfusion rate; (b) liver transection time; (c) total complications.

asymmetry, indicating little possibility of publication bias (Figure 8).

4. Discussion

The meta-analysis included 13 high-quality studies comparing controlled central venous pressure with control in liver surgery, and it demonstrated a strong relationship between blood loss and outflow system of liver blood supply. Meanwhile, controlled venous pressure also had advantages in aspects of other clinical outcome measures.

There was a significant reduction of 2.67 cm H_2O in central venous pressure, and meta-analysis of 10 trials in the random-effects model showed that the total blood loss was significantly reduced. To estimate the total blood loss, four of the analyzed studies collected blood in the container of the aspirator and weighed the soaked gauzes [14, 15, 17, 18], and additionally one study visually evaluated the surgical field [24], while the other studies did not report the methods, so this may be a source of heterogeneity across the studies. We further investigated the blood loss during liver transection in five studies, which was more accurate than total blood loss. Among the studies, four of them performed hepatectomy [14–16, 20] and one performed liver transplantation [19], and there was also a significant reduction in blood loss. In order

to eliminate the influence of transection area in hepatectomy, one study [21] calculated the blood loss per transection area (mL/cm²), and it further demonstrated a significant difference between the groups (P = 0.01).

Further analysis revealed that the transfusion rate was also significantly decreased in IVCC and IAC group, while only one study presented a detailed protocol of transfusion. Although the transfusion protocols between the centers were different and it might cause a heterogeneity, it may not influence the pooled results as the protocols were comparable between the groups in each study. Therefore, combining all the results mentioned above, controlled central venous pressure though IVCC and IAC really significantly improved the intraoperative bleeding control and reduced the blood loss and thus induced a lower transfusion rate.

In aspects of other clinical outcomes, controlled venous pressure might also decrease operation time, while metaanalysis result of liver transection time revealed that there was no significant difference.

For safety, controlled venous pressure achieved a lower incidence of complications mainly in IAC subgroup, and further analysis of diagnosis only found a significant difference in chest infection. Many concerns about abnormal homodynamic did not have significant differences between the groups, perhaps due to the optimal intraoperative anesthetic control [22]. Liver function and renal function were monitored in each study, and relevant indexes including alanine transaminase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN) were influenced, whereas they almost recovered to normal level in postoperative three days, while blocked venous blood from infrahepatic vena cava may induce some risks of incidence of heart disorder (RR = 1,36, P = 0.76), which might involve the opening of collateral circulation and increased blood and pressure in azygos vein from hemiazygos vein and accessory hemiazygos vein.

Further comparisons between IVCC and IAC were conducted using both traditional meta-analysis and network meta-analysis. There was no significant difference in aspects of center vein pressure reduction, transfusion rate, and total complications, while different results existed in aspects of blood loss and operation time. Meta-analysis based on two trials revealed that IVCC significantly decreased total blood, blood loss during transection, total operation time, and liver transection time. Network meta-analysis showed that there was no significant difference between the groups. Besides, compared with IAC, IVCC was really easy to realize as it only needs to clamp the IVC briefly with a vascular clamp before the actual transection [21, 22]. Although we cannot accurately define a superiority between them, current evidence strongly demonstrated that IVCC was not inferior to IAC in aspects of clinical outcome measures, and it still had distinct advantages in feasibility.

Limitations that existed in the meta-analysis were as follows. (1) For all the surgeries, surgeon's experience played important roles in clinical outcomes [26]. We could only ensure it was comparable in each study, and the difference between studies might be the most influencing factors and sources of heterogeneity, which could not be overcome. (2) Other factors such as surgical equipment, operation environment, and characteristics of participants were also different. Although comparable in each study, they also had some negative influence. (3) Although IVCC was not worse than IAC, the difference between them still needs to be explored and confirmed in future studies.

In conclusion, controlled venous pressure significantly decreased central venous pressure and achieved improvement of bleeding control in liver surgery. It reduced total incidence of complications, while it caused some concerns about heart disorder. Although IVCC was not worse than IAC in clinical treatment efficacy, a superiority between them still needs to be explored in the future.

Conflict of Interests

All the authors state that there was no conflict of interests.

References

 M. S. Ascha, I. A. Hanouneh, R. Lopez, T. A.-R. Tamimi, A. F. Feldstein, and N. N. Zein, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis," *Hepatology*, vol. 51, no. 6, pp. 1972–1978, 2010.

- [2] Y. Kishi, K. Shimada, S. Nara et al., "Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma," *World Journal of Hepatology*, vol. 6, no. 12, pp. 836–843, 2014.
- [3] K. S. Gurusamy, T. Pissanou, H. Pikhart, J. Vaughan, A. K. Burroughs, and B. R. Davidson, "Methods to decrease blood loss and transfusion requirements for liver transplantation," *The Cochrane Database of Systematic Reviews*, no. 12, Article ID CD009052, 2011.
- [4] F. U. Si-Yuan, L. W. Yee, L. Guang-Gang et al., "A prospective randomized controlled trial to compare Pringle maneuver, hemihepatic vascular inflow occlusion, and main portal vein inflow occlusion in partial hepatectomy," *The American Journal* of Surgery, vol. 201, no. 1, pp. 62–69, 2011.
- [5] Z. Li, Y.-M. Sun, F.-X. Wu, L.-Q. Yang, Z.-J. Lu, and W.-F. Yu, "Controlled low central venous pressure reduces blood loss and transfusion requirements in hepatectomy," *World Journal of Gastroenterology*, vol. 20, no. 1, pp. 303–309, 2014.
- [6] H. Chen, N. B. Merchant, and M. S. Didolkar, "Hepatic resection using intermittent vascular inflow occlusion and low central venous pressure anesthesia improves morbidity and mortality," *Journal of Gastrointestinal Surgery*, vol. 4, no. 2, pp. 162–167, 2000.
- [7] J. W. Sear, "Kidney dysfunction in the postoperative period," *British Journal of Anaesthesia*, vol. 95, no. 1, pp. 20–32, 2005.
- [8] W. J. Fawcett, N. F. Quiney, and N. D. Karanjia, "Central venous oxygen saturation, base excess and lactate changes during induced hypovolaemic liver resection," *Anaesthesia*, vol. 62, no. 3, pp. 312–313, 2007.
- [9] C.-X. Lin, Y. Guo, W. Y. Lau et al., "Optimal central venous pressure during partial hepatectomy for hepatocellular carcinoma," *Hepatobiliary and Pancreatic Diseases International*, vol. 12, no. 5, pp. 520–524, 2013.
- [10] J. P. T. Higgins and S. Green, Eds., Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1, The Cochrane Collaboration, 2008, http://www.cochrane-handbook.org/.
- [11] A. Stang, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses," *European Journal of Epidemiology*, vol. 25, no. 9, pp. 603–605, 2010.
- [12] G. A. Wells, S. A. Sultan, L. Chen, M. Khan, and D. Coyle, *Indirect Treatment Comparison [Computer Program]. Version* 1.0, Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada, 2009.
- [13] T. Otsubo, K. Takasaki, M. Yamamoto et al., "Bleeding during hepatectomy can be reduced by clamping the inferior vena cava below the liver," *Surgery*, vol. 135, no. 1, pp. 67–73, 2004.
- [14] X.-P. Chen, Z.-W. Zhang, B.-X. Zhang et al., "Modified technique of hepatic vascular exclusion: effect on blood loss during complex mesohepatectomy in hepatocellular carcinoma patients with cirrhosis," *Langenbeck's Archives of Surgery*, vol. 391, no. 3, pp. 209–215, 2006.
- [15] W.-D. Wang, L.-J. Liang, X.-Q. Huang, and X.-Y. Yin, "Low central venous pressure reduces blood loss in hepatectomy," *World Journal of Gastroenterology*, vol. 12, no. 6, pp. 935–939, 2006.
- [16] M. Kato, K. Kubota, J. Kita, M. Shimoda, K. Rokkaku, and T. Sawada, "Effect of infra-hepatic inferior vena cava clamping on bleeding during hepatic dissection: a prospective, randomized, controlled study," *World Journal of Surgery*, vol. 32, no. 6, pp. 1082–1087, 2008.
- [17] Y. Liu, M. Cai, X. Peng, S. Duan, Y. Lai, and Y. Li, "Effect of controlled low central venous pressure on renal function in

major liver resection," *The Chinese-German Journal of Clinical Oncology*, vol. 7, no. 1, pp. 7–9, 2008.

- [18] K. Uchiyama, M. Ueno, S. Ozawa et al., "Half clamping of the infrahepatic inferior vena cava reduces bleeding during a hepatectomy by decreasing the central venous pressure," *Lan-genbeck's Archives of Surgery*, vol. 394, no. 2, pp. 243–247, 2009.
- [19] Z.-Y. Feng, X. Xu, S.-M. Zhu, B. Bein, and S.-S. Zheng, "Effects of low central venous pressure during preanhepatic phase on blood loss and liver and renal function in liver transplantation," *World Journal of Surgery*, vol. 34, no. 8, pp. 1864–1873, 2010.
- [20] J.-F. Liu, M.-H. Chi, J.-H. Zeng et al., "The effect of different hepatic vascular exclusion for massive hemorrhage in hepatectomy," *Chinese Journal of Surgery*, vol. 48, no. 3, pp. 177–180, 2010.
- [21] N. N. Rahbari, M. Koch, J. B. Zimmermann et al., "Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial," *Annals of Surgery*, vol. 253, no. 6, pp. 1102–1110, 2011.
- [22] P. Zhu, W.-Y. Lau, Y.-F. Chen et al., "Randomized clinical trial comparing infrahepatic inferior vena cava clamping with low central venous pressure in complex liver resections involving the Pringle manoeuvre," *British Journal of Surgery*, vol. 99, no. 6, pp. 781–788, 2012.
- [23] J. Yang, C. Sui, T. Kan, B. Li, and Y. Zhou, "Infrahepatic inferior vena cava clamping in hepatectomy for tumors involving hepatocaval confluence," *Asian Journal of Surgery*, vol. 36, no. 3, pp. 111–115, 2013.
- [24] H.-G. Ryu, F. S. Nahm, H.-M. Sohn, E.-J. Jeong, and C.-W. Jung, "Low central venous pressure with milrinone during living donor hepatectomy," *The American Journal of Transplantation*, vol. 10, no. 4, pp. 877–882, 2010.
- [25] B. Wang, H.-K. He, B. Cheng, K. Wei, and S. Min, "Effect of low central venous pressure on postoperative pulmonary complications in patients undergoing liver transplantation," *Surgery Today*, vol. 43, no. 7, pp. 777–781, 2013.
- [26] C. M. Schmidt, O. Turrini, P. Parikh et al., "Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience," *Archives of Surgery*, vol. 145, no. 7, pp. 634–640, 2010.